Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 8348 | 1193 | 43.1 | 92% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | P21 | Author keyword | 28 | 12% | 19% | 221 |
| 2 | P21WAF1 CIP1 | Author keyword | 24 | 23% | 8% | 93 |
| 3 | WAF1 | Author keyword | 12 | 38% | 2% | 24 |
| 4 | P21 GENE | Author keyword | 8 | 70% | 1% | 7 |
| 5 | P21WAF1 | Author keyword | 8 | 15% | 4% | 48 |
| 6 | WAF1 CIP1 | Author keyword | 7 | 64% | 1% | 7 |
| 7 | CIP1 | Author keyword | 7 | 38% | 1% | 15 |
| 8 | SDI1 | Author keyword | 5 | 63% | 0% | 5 |
| 9 | SEZ PATOL GEN C GOLGI | Address | 5 | 55% | 1% | 6 |
| 10 | P21CIP1 WAF1 | Author keyword | 3 | 18% | 1% | 17 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | P21 | 28 | 12% | 19% | 221 | Search P21 | Search P21 |
| 2 | P21WAF1 CIP1 | 24 | 23% | 8% | 93 | Search P21WAF1+CIP1 | Search P21WAF1+CIP1 |
| 3 | WAF1 | 12 | 38% | 2% | 24 | Search WAF1 | Search WAF1 |
| 4 | P21 GENE | 8 | 70% | 1% | 7 | Search P21+GENE | Search P21+GENE |
| 5 | P21WAF1 | 8 | 15% | 4% | 48 | Search P21WAF1 | Search P21WAF1 |
| 6 | WAF1 CIP1 | 7 | 64% | 1% | 7 | Search WAF1+CIP1 | Search WAF1+CIP1 |
| 7 | CIP1 | 7 | 38% | 1% | 15 | Search CIP1 | Search CIP1 |
| 8 | SDI1 | 5 | 63% | 0% | 5 | Search SDI1 | Search SDI1 |
| 9 | P21CIP1 WAF1 | 3 | 18% | 1% | 17 | Search P21CIP1+WAF1 | Search P21CIP1+WAF1 |
| 10 | P21CDKN1A | 3 | 57% | 0% | 4 | Search P21CDKN1A | Search P21CDKN1A |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | P21 | 86 | 20% | 33% | 394 |
| 2 | WAF1 CIP1 | 39 | 46% | 5% | 64 |
| 3 | P53 INDEPENDENT EXPRESSION | 35 | 60% | 3% | 38 |
| 4 | P21WAF1 CIP1 | 30 | 22% | 10% | 121 |
| 5 | P53 INDEPENDENT PATHWAY | 21 | 35% | 4% | 49 |
| 6 | P21WAF1 CIP1 EXPRESSION | 21 | 31% | 5% | 56 |
| 7 | P53 MEDIATED G1 ARREST | 21 | 35% | 4% | 48 |
| 8 | WAF1 | 20 | 53% | 2% | 26 |
| 9 | WAF1 CIP1 GENE | 16 | 48% | 2% | 25 |
| 10 | INHIBITOR P21 | 14 | 36% | 3% | 32 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| p21WAF1 and tumourigenesis: 20 years after | 2013 | 72 | 40 | 60% |
| p21 in cancer: intricate networks and multiple activities | 2009 | 602 | 223 | 39% |
| The role of the cyclin-dependent kinase inhibitor p21 in apoptosis | 2002 | 563 | 168 | 53% |
| Less understood issues: p21(Cip1) in mitosis and its therapeutic potential | 2015 | 4 | 168 | 50% |
| Cyclin-Dependent Kinase Inhibitor p21(Waf1): Contemporary View on Its Role in Senescence and Oncogenesis | 2012 | 45 | 120 | 52% |
| Examination of the expanding pathways for the regulation of p21 expression and activity | 2010 | 139 | 210 | 32% |
| Lost in transcription: p21 repression, mechanisms, and consequences | 2005 | 361 | 78 | 27% |
| The intricacies of p21 phosphorylation - Protein/protein interactions, subcellular localization and stability | 2006 | 89 | 93 | 54% |
| P21 (Waf1/Cip1) as a therapeutic target in breast and other cancers | 2003 | 170 | 49 | 69% |
| Transcriptional regulation of the p21((WAF1/ClP1)) gene | 1999 | 459 | 107 | 36% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | SEZ PATOL GEN C GOLGI | 5 | 55% | 0.5% | 6 |
| 2 | MINIST EDUC BREAST CANC PREVENT TREATME | 2 | 67% | 0.2% | 2 |
| 3 | NEW PROD 4 | 2 | 43% | 0.3% | 3 |
| 4 | ZHANGHAI HOSP | 1 | 100% | 0.2% | 2 |
| 5 | ORAL SURG IMPLANTOL UNIT | 1 | 40% | 0.2% | 2 |
| 6 | COMPARAT PATHOL GRP | 1 | 21% | 0.3% | 4 |
| 7 | AUTOIMMUN MED NURSING HLTH SCI | 1 | 50% | 0.1% | 1 |
| 8 | BANK CYPRUS ONCOL | 1 | 50% | 0.1% | 1 |
| 9 | BIOL CELLULAIRE MOL CONTROLE PROLIFERAT CEL | 1 | 50% | 0.1% | 1 |
| 10 | BIOL INORG CHEM | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000193589 | SKP2//P27KIP1//P27 |
| 2 | 0.0000130022 | P53 GENE//P53 MUTANTS//MUTANT P53 |
| 3 | 0.0000103248 | CYCLIN D1//CYCLIN E//CCND1 |
| 4 | 0.0000091648 | GADD45//GADD45A//GREENSCREEN HC |
| 5 | 0.0000085328 | P14ARF//P16//P16INK4A |
| 6 | 0.0000073188 | SMALL ACTIVATING RNA//SARNA//RNA ACTIVATION |
| 7 | 0.0000061763 | P53 CODON 72//P53 POLYMORPHISM//CODON 72 POLYMORPHISM |
| 8 | 0.0000058509 | E2F//P107//P130 |
| 9 | 0.0000058403 | CELLULAR SENESCENCE//SENESCENCE//BLSC |
| 10 | 0.0000058207 | CAK//CDC2//CYCLIN A1 |